Form 4: Elanco CEO Jeffrey Simmons Buys $1.3 Million in Company Stock
SEC Form 4 Filing
Elanco Animal Health's CEO, Jeffrey Simmons, recently purchased 100,000 shares of the company's common stock at an average price of $13.0061 per share.
Summary
- Elanco Animal Health Inc. CEO Jeffrey N. Simmons purchased 100,000 shares of common stock on August 12, 2024.
- The purchase was made at a weighted average price of $13.0061 per share, with individual prices ranging from $12.9985 to $13.0662.
- Following the transaction, Simmons directly owns 1,358,354 shares and indirectly owns 145,000 shares through a revocable trust.
- The indirect holdings of 145,000 shares are held by a revocable trust.
- Simmons also acquired 1,899 shares under Elanco's Employee Stock Purchase Plan on April 30, 2024.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive. The CEO's stock purchase suggests confidence in the company's prospects, which is generally viewed favorably by investors. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CEO's purchase of a significant amount of company stock could be interpreted as a positive signal, indicating confidence in Elanco's future performance.
Industry Context
Insider buying is often seen as a positive sign in the market, suggesting that a company's leadership believes the stock is undervalued. It's a common practice, and the details are required to be disclosed to the SEC.
Comparison to Industry Standards
- Comparing this purchase to similar insider transactions at Zoetis or Boehringer Ingelheim Animal Health would provide context on the scale and potential impact of this buy.
- For example, if the CEO of Zoetis made a similar purchase, the market reaction and subsequent stock performance could be analyzed to gauge the typical impact of such events in the animal health industry.
- Benchmarking against historical insider trading data for Elanco itself could also reveal whether this purchase is unusually large or consistent with past behavior.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal, potentially leading to increased investor confidence.
- The purchase could have a minor positive impact on employee morale, as it suggests the CEO is invested in the company's success.
Key Dates
| Date | Description |
|---|---|
| April 30, 2024 | Acquisition of 1,899 shares under Elanco Animal Health Inc.'s Employee Stock Purchase Plan |
| August 12, 2024 | Date of the transaction where Jeffrey N. Simmons purchased 100,000 shares of Elanco Animal Health Inc. common stock |
| August 13, 2024 | Date of signature for the SEC Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.